[1] Lage A, Perez R, Fernandez LE. Therapeutic cancer vaccines: at midway between immunology andpharmacology[J]. Curr Cancer Drug Targets, 2005, 5(8):611-627.
[2] Livingston PO, Hood C, Krug LM, et al. Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy[J]. Cancer Immunol Immunother, 2005, 54(10):1018-1025.
[3] Livingston PO, Ragupathi G. Cancer vaccines targeting carbohydrate antigens[J]. Hum Vaccin, 2006, 2(3):137-143.
[4] de León J, Fernández A, Clavell M, et al. Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25-effector and naturally occurring CD4+CD25+ regulatory T cells function[J]. Int Immunol, 2008, 20(4):591-600.
[5] Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy[J]. Nature, 2007, 445(7130):851-857.
[6] Fredman P, Hedberg K, Brezicka T. Gangliosides as therapeutic targets for cancer[J]. BioDrugs, 2003, 17(3):155-167.
[7] Schlenzka W, Shaw L, Kelm S, et al. CMP-N-Acetylneuraminic acid hydroxylase: the first cytosolic Rieske iron-sulphur protein to be described in Eukarya[J]. FEBS Lett, 1996, 385(3):197-200.
[8] Irie A, Suzuki A. CMP-N-Acetylneuraminic acid hydroxylase is exclusively inactive in humans[J]. Biochem Biophys Res Commun, 1998, 248(2):330-333.
[9] Marquina G, Waki H, Fernandez LE, et al. Gangliosides expressed in human breast cancer[J]. Cancer Res, 1996, 56(22):5165-5171.
[10] Oliva JP, Valdés Z, Casacó A, et al. Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc[J]. Breast Cancer Res Treat, 2006, 96(2):115?-121.
[11] Osorio M, Gracia E, Rodríguez E, et al. Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: result of a Phase lb/lla study[J]. Cancer Biol Ther, 2008, 7(4):489-495.
[12] Scursoni AM, Galluzzo L, Camarero S, et al. Detection and characterization of N-glycolyated gangliosides in Wilms tumor by immunohistochemistry[J]. Pediatr Dev Pathol, 2010, 13(1):18-23.
[13] van Cruijsen H, Ruiz MG, van der Valk P, et al. Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer[J]. BMC Cancer, 2009, 9:180.
[14] Blanco R, Rengifo E, Cedeno M, et al. Immunoreactivity of the 14F7 mab raised against N-Glycolyl GM3 ganglioside in epithelial malignant tumors from digestive system[J]. ISRN Gastroenterol, 2011, 2011:645641.
[15] Scursoni AM, Galluzzo L, Camarero S, et al. Detection of N-Glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer[J]. Clin Dev Immunol, 2011, 2011:245181.
[16] de Leòn J, Fernández A, Mesa C, et al. Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T Cells[J]. Cancer Immunol Immunother, 2006, 55(4):443-450.
[17] Roque-Navarro L, Chakrabandhu K, de León J, et al. Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity[J]. Mol Cancer Ther, 2008, 7(7):2033-2041.
[18] Carr A, Mesa C, del Carmen Arango M, et al. In vivo and in vitro anti-tumor effect of 14F7 monoclonal antibody[J]. Hybrid Hybridomics, 2002, 21(6):463-468.
[19] Alfonso M, Diaz A, Hernández AM, et al. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients[J]. J Immunol, 2002, 168(5):2523-2529.
[20] Hernández AM, Rodriguez N, González JE, et al. Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism[J]. J Immunol, 2011, 186(6):3735-3744.
[21] Doré JF, Portoukalian J, Berthier Vergnes O, et al. Response in patients with melanoma to immunization using melanoma oncolysates of vaccine virus [J]. Bull Cancer, 1990, 77(9):881-891.
[22] Nakarai H, Chandler PJ, Kano K, et al. Hanganutziu-Deicher antigen as a possible target for immunotherapy of melanoma[J]. Int Arch Allergy Appl Immunol, 1990, 91(3):323-328.
[23] Kawachi S, Saida T. Analysis of the expression of Hanganutziu-Deicher (HD) antigen in human malignant melanoma[J]. J Dermatol, 1992, 19(11):827-830.
[24] Carr A, Mullet A, Mazorra Z, et al. A mouse IgG1 monoclonal antibody specific for N-Glycolyl GM3 ganglioside recognized breast and melanoma tumors[J]. Hybridoma, 2000, 19(3): 241-247. |